Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001641172-25-020609
Filing Date
2025-07-22
Accepted
2025-07-22 17:04:26
Documents
5

Document Format Files

Seq Description Document Type Size
1 DEFM14A formdefm14a.htm DEFM14A 6523586
2 GRAPHIC chart_02.jpg GRAPHIC 286784
3 GRAPHIC chart_03.jpg GRAPHIC 306737
4 GRAPHIC annex-c_001.jpg GRAPHIC 9262
5 GRAPHIC annex-c_003.jpg GRAPHIC 7010
  Complete submission text file 0001641172-25-020609.txt   7364318
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-13341 | Film No.: 251140905
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)